We evaluated the repercussions of α-tocopherol addition on (i) imatinib and nilotinib treatment, two drugs used to inhibit the oncogenic fusion protein BCR-ABL in CML and (ii) on gefitinib effect, a well described EGFR inhibitor usually prescribed for non-small cell lung cancer. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.